OakChart

FibroBiologics Inc

FBLGHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 1:21 PM ET

0.9210-0.0029 (-0.31%)
2026-11-11 19:21 CET
Market cap
6.15 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-18.14 USD m
Free cash flow, TTM
-14.80 USD m
EPS diluted, TTM
-5.64
P/E
-
Compare

Price

FBLG against its 20, 50 and 200-day averages
2050200miss
2.004.006.001.5M2.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FBLGclose 0.9220-day 0.9650-day 1.21200-day 2.140.92

90.4% under the 52-week high of 9.60 on 3 Mar 2026. 52-week low 0.62 on 27 Jul 2026. Last 15 sessions, 39.3% high to low

Profile

FBLG
52-week range, 3% of the way up
0.629.60

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.

Employees15
IPOJan 31, 2024
Beta1.77
ATR, 14d0.09
Rel volume0.15
Short float6.03%
Insider own16.72%
Inst own12.47%

Snapshot

6 groups

Valuation

Index-
Market Cap6.13M
Enterprise Value4.07M
Income-18.14M
Sales0.00M
Book/sh0.76
Cash/sh0.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPOJan 31, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.21
P/C1.74
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.64
Current Ratio2.64
Debt/Eq0.31
LT Debt/Eq0.23
Option/ShortNo / Yes

Earnings

EPS (ttm)-5.64
EPS next Y-3.25
EPS next Q-0.63
EPS this Y64.29%
EPS next Y-8.33%
EPS next 5Y21.91%
EPS past 3/5Y-38.37% -71.12%
Sales past 3/5Y- -
EPS Y/Y TTM22.10%
Sales Y/Y TTM-
EPS Q/Q72.78%
Sales Q/Q-
EarningsJul 31 AMC
EPS/Sales Surpr.29.03% -

Ownership

Insider Own16.72%
Insider Trans0.00%
Inst Own12.47%
Inst Trans10.51%
ROA-166.14%
ROE-660.08%
ROIC-317.34%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.62%
SMA50-23.97%
SMA200-56.87%
Trades-

Technical

Shs Outstand6.08M
Shs Float5.54M
Short Float6.03%
Short Ratio1.73
Short Interest0.33M
52W High9.60 -90.40%
52W Low0.62 48.54%
Volatility7.91% 9.10%
ATR (14)0.09
RSI (14)38.69
Beta1.77
Rel Volume0.15
Avg Volume193.35K
Volume17,703

Performance

Perf Week-4.90%
Perf Month-4.05%
Perf Quarter-19.91%
Perf Half Y-18.50%
Perf YTD-79.52%
Perf Year-86.36%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price6.00
Prev Close0.92
Price0.92
Change %-0.31%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Dec 12, 2024InitiatedRRodman & RenshawBuy$12+1,202.9%
Oct 30, 2024InitiatedHH.C. WainwrightBuy$12+1,202.9%
Sep 24, 2024InitiatedMMaxim GroupBuy$12+1,202.9%

Peers

Mkt cap
TickerCompanyMkt cap
BRTXBioRestorative Therapies Inc2.08M
CELZCreative Medical Technology Holdings Inc4.71M
LGVNLongeveron Inc9.40M
PLURPluri Inc15.51M
CELUCelularity Inc24.42M
BSEMBioStem Technologies Inc25.91M
LCTXLineage Cell Therapeutics Inc280.72M
MDXGMimedx Group Inc494.69M
BBLGBone Biologics Corp1.23M
CAPRCapricor Therapeutics Inc612.21M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Khoja HamidChief Scientific OfficerMar 04 '26Buy0.3830,00011,40061,250Mar 05 08:00 AM
O'HEERON PETECHIEF EXECUTIVE OFFICERMar 03 '26Buy0.4118,2007,3735,942,275Mar 04 05:50 PM
O'HEERON PETECHIEF EXECUTIVE OFFICERMar 02 '26Buy0.3517,4286,1525,924,075Mar 04 05:50 PM
O'HEERON PETECHIEF EXECUTIVE OFFICERMar 04 '26Buy0.3815,8726,0065,958,147Mar 04 05:50 PM
Davis JasonChief Financial OfficerMar 02 '26Buy0.4170,00028,97370,000Mar 03 08:00 AM
GARCIA RUBEN AGeneral CounselFeb 27 '26Buy0.3340,00013,056180,000Mar 02 09:15 AM
GARCIA RUBEN AGeneral CounselDec 11 '25Buy0.34140,00047,600140,000Dec 12 07:16 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents (PR Newswire)
  • FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting (PR Newswire)
  • FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs (PR Newswire)
  • FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body (PR Newswire)
  • FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity (PR Newswire)
  • Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) (FinanceWire)
  • FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer (PR Newswire)
  • FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing (PR Newswire) -9.74%
  • FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media (PR Newswire) +22.67%
  • FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial (PR Newswire) +5.67%
  • FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia (Proactive)
  • FibroBiologics Regains Compliance with Nasdaq Trading Rules (PR Newswire)
  • FibroBiologics Appoints Leigh Steinberg to Board of Directors (PR Newswire) -6.25%
  • FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease (PR Newswire) +8.40%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-07-31-0.660-0.930-1.0000.000.001
2026Q12026-04-30-1.310-1.334-1.3250.000.004
2025Q42026-02-24-0.930-1.440-0.9750.000.003
2025Q32025-10-31-2.600-2.400-2.6830.000.003
2025Q22025-07-31-2.400-2.400-2.4110.000.003
2025Q12025-05-28-2.800-2.500-2.7080.000.004
2024Q42025-03-31-1.866-1.840-1.8220.000.005
2024Q32024-11-12-0.200-1.444-0.2980.000.004
2024Q22024-08-280.5880.6000.5490.000.001
2024Q12024-05-29-5.400--5.1710.00--
2026Q3---0.630--0.001
2026Q4---0.630--0.001
2027Q1---0.768---1
2027Q2---0.728---1
2027Q3---0.784---1
2027Q4---0.870---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-6.800-6.840-6.7900.000.00
2025FY-8.400-9.067-8.4000.000.00
2026FY--3.000--0.00
2027FY--3.250--0.00
2028FY--4.000--0.00
2029FY--4.890--0.00
2030FY--4.230--19.09

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-031000.000.000.00
2026Q3S2026-07-101000.000.000.00
2026Q3S2026-05-012000.000.000.00
2026Q3S2026-02-252000.000.000.00
2026Q3S2025-11-112000.000.000.00
2026Q3S2025-11-102000.000.000.00
2026Q3S2025-11-092000.000.000.00
2026Q3S2025-11-082000.000.000.00
2026Q3S2025-11-072000.000.000.00
2026Q3S2025-11-062000.000.000.00
2026Q3S2025-11-052000.000.000.00
2026Q3S2025-11-042000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00

Estimate history

EPS, annual-0.974-3.152-13.502-6.79-8.35-5.64
Period20212022202320242025TTM
EPS, quarterly0.549-0.298-1.822-2.708-2.411-2.683-0.975-1.325-0.656
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.6251.6251.4121.7543.3266.081
Period20212022202320242025MRQ
Shares, quarterly1.6361.6961.7541.8872.0432.4133.3263.5136.081
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.860.830.570.440.090.00
Gross Profit-0.86-0.83-0.57-0.44-0.090.00
Selling, General and Administrative Excl. Other15.8715.8213.168.454.371.58
Research and Development8.207.414.352.321.150.52
Other Operating Expense0.000.000.000.000.000.00
Operating Income-16.73-16.65-13.74-8.89-4.47-1.58
Interest Expense-0.200.020.150.650.00
Unusual Expense1.241.42-5.957.240.000.00
Net Income Before Taxes-18.14-18.65-11.16-16.48-5.12-1.58
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-18.14-18.65-11.16-16.48-5.12-1.58
Net Income From Continuing Operations-18.14-18.65-11.16-16.48-5.12-1.58
Net Income-18.14-18.65-11.16-19.06-5.12-1.58
EPS (Recurring)-2.75-7.90-9.33-9.91-3.15-0.97
EPS (Basic, Before Extraordinaries)-5.64-8.35-6.79-13.50-3.15-0.97
EPS (Diluted)-5.64-8.35-6.79-13.50-3.15-0.97
EBITDA-15.87-15.82-13.16-8.45-4.37-1.58
Non-Operating Income (Expense)0.04-0.37-3.36-0.210.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense2.812.692.221.760.270.00
Shares Outstanding6.083.331.751.411.621.62
Market Capitalization6.156.1570.1775.98--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.160.240.230.230.210.160.150.14
Gross Profit-0.16-0.24-0.23-0.23-0.21-0.16-0.15-0.14
Selling, General and Administrative Excl. Other3.874.832.364.814.284.373.563.21
Research and Development1.662.950.802.792.041.781.311.18
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.03-5.07-2.59-5.04-4.49-4.53-3.71-3.35
Interest Expense0.010.000.20---0.010.01
Unusual Expense0.00-0.050.480.81-0.410.53-2.25-2.78
Net Income Before Taxes-4.12-5.00-3.24-5.78-4.66-4.97-3.10-0.50
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.12-5.00-3.24-5.78-4.66-4.97-3.10-0.50
Net Income From Continuing Operations-4.12-5.00-3.24-5.78-4.66-4.97-3.10-0.50
Net Income-4.12-5.00-3.24-5.78-4.66-4.97-3.10-0.50
EPS (Recurring)-0.66-1.34-0.87-2.42-2.56-2.50-2.75-1.46
EPS (Basic, Before Extraordinaries)-0.66-1.33-0.98-2.68-2.41-2.71-1.82-0.30
EPS (Diluted)-0.66-1.33-0.98-2.68-2.41-2.71-1.82-0.30
EBITDA-3.87-4.83-2.36-4.81-4.28-4.37-3.56-3.21
Non-Operating Income (Expense)-0.080.020.030.07-0.570.10-1.640.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.710.690.700.700.730.550.590.57
Shares Outstanding6.083.513.332.412.041.891.751.70
Market Capitalization6.154.5014.9626.3625.4233.9670.17104.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments4.8913.989.162.270.41
Short Term Receivables0.000.000.000.300.00
Inventories0.000.000.000.000.00
Other Current Assets1.460.240.050.060.06
Total Current Assets6.3514.239.212.620.47
Net Property, Plant & Equipment3.222.222.612.200.00
Total Investments and Advances0.000.000.000.000.00
Intangible Assets-0.000.000.000.00
Deferred Tax Assets9.745.68---
Other Assets0.050.000.000.000.00
Total Assets19.3622.1211.824.820.47
Short Term Debt Incl. Current Port. of LT Debt0.719.570.365.781.52
Accounts Payable0.942.701.380.490.23
Other Current Liabilities0.110.467.440.800.00
Total Current Liabilities1.7612.739.187.071.76
Long Term Debt1.700.981.391.750.00
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities9.745.68---
Other Liabilities0.000.000.000.000.00
Total Liabilities13.2119.3910.578.821.76
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity6.162.731.25-4.00-1.29
Total Shareholders Equity6.162.731.25-4.00-1.29
Accumulated Minority Interest0.000.000.000.000.00
Total Equity6.162.731.25-4.00-1.29
Total Liabilities & Stockholders Equity19.3622.1211.824.820.47
Book Value Per Share1.851.560.89-2.46-0.79
Tangible Book Value Per Share1.851.560.89-2.46-0.79
Full-Time Employees151310--
Price to Book Ratio1.2125.6627.76--
Return on Assets-89.89-65.76-198.08-193.54-
Return on Equity-419.44-559.73---
Return on Invested Capital-237.23-300.11-624.91--
Quick Ratio3.611.121.000.370.27
Current Ratio3.611.121.000.370.27

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-18.14-18.65-11.16-16.48-5.12-1.58
Depreciation0.860.830.570.440.090.00
Other Funds (Non Cash)4.014.73-1.879.150.650.00
Funds from Operations-13.26-13.08-12.46-6.89-4.37-1.58
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.53-3.310.560.490.310.17
Cash from Operating Activities-14.79-16.39-11.90-6.40-4.07-1.41
Capital Expenditures-0.01-0.26-0.18-0.490.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.26-0.18-0.490.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock12.746.597.5116.142.150.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock12.746.597.5116.142.150.00
Proceedsfrom Stock Options10.166.597.5116.142.150.00
Issuance or Reduction of Debt, Net-3.280.979.400.003.711.52
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-2.350.060.29
Other Financing Activities Uses0.000.000.00-2.650.000.00
Cash from Financing Activities9.477.5716.9113.795.921.82
Net Change in Cash-5.33-9.094.826.901.860.41
Free Cash Flow-14.80-16.66-12.09-6.90-4.07-1.41
Preferred Dividends (Cash Flow)-0.000.00-0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments3.521.484.894.878.858.67
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.331.421.460.371.330.66
Total Current Assets5.852.906.355.2410.189.33
Net Property, Plant & Equipment2.032.983.223.463.682.10
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets-----0.00
Deferred Tax Assets--9.74---
Other Assets0.050.050.050.050.050.00
Total Assets7.935.9419.368.7413.9111.43
Short Term Debt Incl. Current Port. of LT Debt0.380.970.715.228.696.25
Accounts Payable1.820.850.941.071.801.42
Other Current Liabilities0.010.010.110.440.470.54
Total Current Liabilities2.211.831.766.7210.968.21
Long Term Debt1.081.511.701.902.080.86
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--9.74---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.293.3413.218.6213.059.08
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.642.606.160.120.862.35
Total Shareholders Equity4.642.606.160.120.862.35
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.642.606.160.120.862.35
Total Liabilities & Stockholders Equity7.935.9419.368.7413.9111.43
Book Value Per Share0.760.741.850.050.421.25
Tangible Book Value Per Share0.760.741.850.050.421.25
Full-Time Employees--15---
Price to Book Ratio1.210.712.43210.8929.5614.45
Return on Assets-166.14-215.16-89.89-192.59-115.89-67.18
Return on Equity-660.08-754.75-419.44-1,292.87--
Return on Invested Capital-72.03-121.68-41.27-285.76-158.27-154.46
Quick Ratio2.641.593.610.780.931.14
Current Ratio2.641.593.610.780.931.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.12-5.00-3.24-5.78-4.66-4.97
Depreciation0.160.240.230.230.210.16
Other Funds (Non Cash)0.680.641.181.520.951.08
Funds from Operations-3.28-4.12-1.83-4.03-3.50-3.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.01-0.24-1.340.06-0.48-1.55
Cash from Operating Activities-3.29-4.36-3.16-3.97-3.98-5.28
Capital Expenditures0.000.000.00-0.01-0.21-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.01-0.21-0.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.450.716.590.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.450.716.590.000.000.00
Proceedsfrom Stock Options2.860.716.590.000.000.00
Issuance or Reduction of Debt, Net-0.120.25-3.400.004.380.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.320.953.190.004.380.00
Net Change in Cash2.03-3.410.03-3.980.18-5.32
Free Cash Flow-3.29-4.36-3.16-3.98-4.20-5.32

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.03%0.3M5.5M212.13K
2026-10-155.97%0.3M5.5M208.99K
2026-09-309.42%0.5M5.5M197.02K
2026-09-1511.95%0.7M5.5M218.48K
2026-08-317.17%0.4M5.8M184.46K
2026-08-142.46%0.1M5.8M151.71K
2026-07-312.05%0.1M5.6M212.73K
2026-07-151.38%0.1M5.1M231.58K
2026-06-303.09%0.1M4.4M479.68K
2026-06-153.12%0.1M4.4M447.98K
2026-05-293.39%0.1M4.0M440.90K
2026-05-155.48%0.2M4.3M431.73K
2026-04-302.73%0.1M4.3M344.40K
2026-04-153.41%0.1M2.9M322.02K
2026-03-317.30%0.2M2.9M218.21K
2026-03-131.52%0.0M2.9M92.27K
2026-02-271.18%0.0M2.8M91.67K
2026-02-131.11%0.0M2.8M99.79K
2026-01-301.52%0.0M2.8M98.12K
2026-01-150.67%0.0M2.8M99.87K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-19EFFECTEffectiveness filing by commission orderSEC
2026-10-19EFFECTEffectiveness filing by commission orderSEC
2026-10-13DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-13POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-10-13POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-10-088-KCurrent report2026-10-07SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-09-17SCHEDULE 13DSEC
2026-09-16DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-09DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-013Initial statement of beneficial ownership of securities2026-08-20SEC
2026-08-248-KCurrent report2026-08-20SEC
2026-08-14SCHEDULE 13GSEC
2026-07-3110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-31DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-17SEC
2026-07-248-KCurrent report2026-07-22SEC
2026-07-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-17SEC
2026-07-16EFFECTEffectiveness filing by commission orderSEC
2026-07-163Initial statement of beneficial ownership of securities2026-07-08SEC
2026-07-16424B3SEC
2026-07-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-07-098-KCurrent report2026-07-02SEC
2026-06-29DNotice of sales of securities on Form D (Regulation D)SEC
2026-06-298-KCurrent report2026-06-25SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-23SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0359.90K500
2026-0213.06K100
2026-010000
2025-1247.60K100
2025-110000

Institutional holders

Manager% owned
Cascade Financial Partners, LLC2.09%
Fund Evaluation Group, LLC0.99%
VANGUARD CAPITAL MANAGEMENT LLC0.53%
Qube Research & Technologies Ltd0.47%
GEODE CAPITAL MANAGEMENT, LLC0.45%
IFP Advisors, Inc0.41%
BlackRock, Inc.0.35%
VANGUARD FIDUCIARY TRUST CO0.12%
Tower Research Capital LLC0.09%
OSAIC HOLDINGS, INC.0.05%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.53%
Fidelity Extended Market Index Fund0.36%
Fidelity Series Total Market Index Fund0.04%
Fidelity Total Market Index Fund0.03%
Fidelity Nasdaq Composite Index Fund0.02%

OakChart. FBLG. Cached 15 minutes.